|
Market Closed -
Australian S.E.
14:10:07 10/09/2026 HKT
|
5-day change | 1st Jan Change | ||
| 0.3700 AUD | +4.23% |
|
+2.78% | -43.08% |
| 08-31 | Recce Pharmaceuticals Ltd Reports Earnings Results for the Full Year Ended June 30, 2026 | CI |
| 08-31 | Recce Pharmaceuticals Ltd Auditor Raises 'Going Concern' Doubt | CI |
| Market Cap | 113M 81.14M 69.78M 65.84M 59.98M 112M 7.76B 784M 302M 3.93B 305M 298M 12.5B | P/E 2027 * |
-4.35x | P/E 2028 * | 3.33x |
|---|---|---|---|---|---|
| Enterprise Value | 138M 99.04M 85.17M 80.36M 73.21M 137M 9.47B 957M 368M 4.8B 372M 364M 15.25B | EV / Sales 2027 * |
11.1x | EV / Sales 2028 * | 1.2x |
| Free-Float |
62.73% | Yield 2027 * |
-
| Yield 2028 * | - |
Australian S.E.AUD
| Markets | Quality | ||
|---|---|---|---|
Australian S.E.
| RCE | Delayed | |
Deutsche Boerse AG
| R9Q | Delayed | |
Börse Stuttgart
| R9Q | Delayed | |
Boerse Muenchen
| R9Q | Real-time | |
Tradegate
| R9Q | Real-time |
| 1 day | +4.23% | ||
| 1 week | +2.78% | ||
| Current month | -1.33% | ||
| 1 month | -1.33% | ||
| 3 months | -27.45% | ||
| 6 months | -13.95% | ||
| Current year | -43.08% |
| 1 week | 0.34 | 0.37 | |
| 1 month | 0.34 | 0.38 | |
| Current year | 0.34 | 0.73 | |
| 1 year | 0.34 | 0.73 | |
| 3 years | 0.28 | 0.73 | |
| 5 years | 0.28 | 1.38 | |
| 10 years | 0.13 | 1.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
James Graham
CEO | Chief Executive Officer | - | 28/08/2020 |
Justin Reynolds
DFI | Director of Finance/CFO | - | - |
Michele Dilizia
CTO | Chief Tech/Sci/R&D Officer | - | 30/09/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Michele Dilizia
BRD | Director/Board Member | - | 01/10/2012 |
James Graham
BRD | Director/Board Member | - | 01/05/2012 |
| Director/Board Member | - | 01/09/2022 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 31/7/26 | Buy | Chief Executive Officer | 25,000 | 0.0083% | ||
| 31/7/26 | Buy | Director | 75,000 | 0.0250% | ||
| 31/7/26 | Buy | Director | 37,500 | 0.0125% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +4.23% | +2.78% | -22.92% | -43.08% | 78.27M | ||
| +0.08% | -3.07% | +48.95% | +88.73% | 1,002B | ||
| -0.31% | -4.29% | +51.60% | +63.83% | 644B | ||
| +1.33% | -2.46% | +19.93% | +70.30% | 443B | ||
| -0.63% | -3.09% | +29.84% | +36.08% | 343B | ||
| +0.43% | -14.61% | +11.32% | +26.98% | 262B | ||
| +0.93% | -3.19% | -1.31% | +11.96% | 245B | ||
| -2.20% | -13.85% | +37.38% | +46.19% | 212B | ||
| -0.90% | -5.06% | -18.47% | -58.14% | 199B | ||
| -0.61% | -4.27% | +25.61% | +87.90% | 181B | ||
| Average | +0.41% | -4.64% | +18.19% | +33.08% | 352.98B | |
| Weighted average by Cap. | +0.12% | -4.24% | +31.97% | +55.99% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 12.5M 8.96M 7.71M 7.27M 6.62M 12.38M 857M 86.6M 33.33M 435M 33.65M 32.92M 1.38B | 54.3M 38.94M 33.49M 31.6M 28.79M 53.81M 3.72B 376M 145M 1.89B 146M 143M 6B |
| Net income | -25.1M -18M -15.48M -14.61M -13.31M -24.87M -1.72B -174M -66.95M -873M -67.59M -66.11M -2.77B | 33.4M 23.95M 20.6M 19.44M 17.71M 33.1M 2.29B 231M 89.09M 1.16B 89.95M 87.98M 3.69B |
| Net Debt | 24.96M 17.9M 15.4M 14.53M 13.23M 24.74M 1.71B 173M 66.59M 868M 67.23M 65.76M 2.76B | -48.1M -34.5M -29.67M -27.99M -25.5M -47.67M -3.3B -333M -128M -1.67B -130M -127M -5.31B |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/09/26 | A$0.3700 | +4.23% | 97,134 |
| 09/09/26 | A$0.3550 | -4.05% | 29,672 |
| 08/09/26 | A$0.3700 | +2.78% | 242,532 |
| 07/09/26 | A$0.3600 | -2.70% | 59,963 |
| 04/09/26 | A$0.3700 | +2.78% | 75,875 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- RCE Stock
Select your edition
All financial news and data tailored to specific country editions

















